The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus-Like Particles

Overview

Journal Adv Funct Mater

Date 2021 Aug 9

PMID 34366757

Citations 37

Authors

Hui Cai

Sourabh Shukla

Nicole F Steinmetz

Affiliations

Soon will be listed here.

Abstract

Oligodeoxynucleotides (ODNs) with CpG motifs have potent immunostimulatory effects on many subsets of immune cells. For example, Class B CpG-ODNs, such as ODN1826 induce the phagocytic activity of macrophages by activating the Toll-like receptor 9 signaling pathway. Systemic ODN delivery results in unfavorable pharmacokinetic profiles and can trigger adverse effects. To address this issue, plant virus-like particles (VLPs) are developed for the targeted delivery of ODN1826 to tumor-associated macrophages (TAMs). ODN1826 is encapsulated by the in vitro disassembly and reassembly of Cowpea chlorotic mottle virus (CCMV), producing VLPs that are structurally analogous to the native virus. The encapsulation of ODN1826 in CCMV-derived VLPs promotes ODN uptake by TAMs ex vivo and significantly enhance their phagocytic activity. The antitumor activity of the VLPs in vivo is also evaluated, revealing that the direct injection of ODN1826 VLPs into established tumors induces a robust antitumor response by increasing the phagocytic activity of TAMs in the tumor microenvironment. CCMV encapsulation significantly enhances the efficacy of ODN1826 compared to the free drug, slowing tumor growth and prolonging survival in mouse models of colon cancer and melanoma.

Citing Articles

The application of tissue engineering strategies for uterine regeneration.

Chen S, Yoo J, Wang M Mater Today Bio. 2025; 31:101594.

PMID: 40070871 PMC: 11894340. DOI: 10.1016/j.mtbio.2025.101594.

Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.

Hashim G, Shahgolzari M, Hefferon K, Yavari A, Venkataraman S Bioengineering (Basel). 2025; 12(1).

PMID: 39851281 PMC: 11759177. DOI: 10.3390/bioengineering12010007.

Virus nanotechnology for intratumoural immunotherapy.

Omole A, Zhao Z, Chang-Liao S, de Oliveira J, Boone C, Sutorus L Nat Rev Bioeng. 2024; 2(11):916-929.

PMID: 39698315 PMC: 11655125. DOI: 10.1038/s44222-024-00231-z.

Enhanced efficacy of a TLR3 agonist delivered by cowpea chlorotic mottle virus nanoparticles.

Jung E, Foroughishafiei A, Chung Y, Steinmetz N Small Sci. 2024; 4(7).

PMID: 39640945 PMC: 11615967. DOI: 10.1002/smsc.202300314.

Protein Cage Directed Assembly of Binary Nanoparticle Superlattices.

Zhou Y, Shaukat A, Seitsonen J, Rigoni C, Timonen J, Kostiainen M Adv Sci (Weinh). 2024; 11(45):e2408416.

PMID: 39401426 PMC: 11615748. DOI: 10.1002/advs.202408416.

References

Storni T, Ruedl C, Schwarz K, Schwendener R, Renner W, Bachmann M . Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol. 2004; 172(3):1777-85. DOI: 10.4049/jimmunol.172.3.1777. View

Gao M, Ha T, Zhang X, Wang X, Liu L, Kalbfleisch J . The Toll-like receptor 9 ligand, CpG oligodeoxynucleotide, attenuates cardiac dysfunction in polymicrobial sepsis, involving activation of both phosphoinositide 3 kinase/Akt and extracellular-signal-related kinase signaling. J Infect Dis. 2013; 207(9):1471-9. PMC: 3693590. DOI: 10.1093/infdis/jit036. View

Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P . Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017; 14(7):399-416. PMC: 5480600. DOI: 10.1038/nrclinonc.2016.217. View

Dalpke A, Zimmermann S, Albrecht I, Heeg K . Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology. 2002; 106(1):102-12. PMC: 1782689. DOI: 10.1046/j.1365-2567.2002.01410.x. View

Liu H, Moynihan K, Zheng Y, Szeto G, Li A, Huang B . Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014; 507(7493):519-22. PMC: 4069155. DOI: 10.1038/nature12978. View

Comas-Garcia M, Garmann R, Singaram S, Ben-Shaul A, Knobler C, Gelbart W . Characterization of Viral Capsid Protein Self-Assembly around Short Single-Stranded RNA. J Phys Chem B. 2014; 118(27):7510-7519. DOI: 10.1021/jp503050z. View

Mantovani A, Allavena P, Sica A, Balkwill F . Cancer-related inflammation. Nature. 2008; 454(7203):436-44. DOI: 10.1038/nature07205. View

Hanagata N . CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Int J Nanomedicine. 2017; 12:515-531. PMC: 5248940. DOI: 10.2147/IJN.S114477. View

Azizgolshani O, Garmann R, Cadena-Nava R, Knobler C, Gelbart W . Reconstituted plant viral capsids can release genes to mammalian cells. Virology. 2013; 441(1):12-7. DOI: 10.1016/j.virol.2013.03.001. View

10.

Lin A, Almeida J, Bear A, Liu N, Luo L, Foster A . Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One. 2013; 8(5):e63550. PMC: 3655178. DOI: 10.1371/journal.pone.0063550. View

11.

Lam P, Steinmetz N . Delivery of siRNA therapeutics using cowpea chlorotic mottle virus-like particles. Biomater Sci. 2019; 7(8):3138-3142. PMC: 6705399. DOI: 10.1039/c9bm00785g. View

12.

Wang C, Beiss V, Steinmetz N . Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties. J Virol. 2019; 93(21). PMC: 6803287. DOI: 10.1128/JVI.00129-19. View

13.

Valmori D, Souleimanian N, Tosello V, Bhardwaj N, Adams S, ONeill D . Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007; 104(21):8947-52. PMC: 1885608. DOI: 10.1073/pnas.0703395104. View

14.

Zhang L, Zhu G, Mei L, Wu C, Qiu L, Cui C . Self-Assembled DNA Immunonanoflowers as Multivalent CpG Nanoagents. ACS Appl Mater Interfaces. 2015; 7(43):24069-74. PMC: 4898273. DOI: 10.1021/acsami.5b06987. View

15.

Mutwiri G, Nichani A, Babiuk S, Babiuk L . Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004; 97(1):1-17. DOI: 10.1016/j.jconrel.2004.02.022. View

16.

Liu M, OConnor R, Trefely S, Graham K, Snyder N, Beatty G . Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Nat Immunol. 2019; 20(3):265-275. PMC: 6380920. DOI: 10.1038/s41590-018-0292-y. View

17.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

18.

Krieg A . Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007; 117(5):1184-94. PMC: 1857270. DOI: 10.1172/JCI31414. View

19.

SANDS H, Cocuzza A, Hobbs F, Chidester D, Trainor G . Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994; 45(5):932-43. View

20.

Ali A, Roossinck M . Rapid and efficient purification of Cowpea chlorotic mottle virus by sucrose cushion ultracentrifugation. J Virol Methods. 2006; 141(1):84-6. DOI: 10.1016/j.jviromet.2006.11.038. View